My Portfolio

Intellia Therapeutics Inc NTLA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 7:53 PM EDT

12.70

-0.32 (-2.46%)

Volume

88,319

13.02

-0.11 (-0.84%)

Volume

2,982,266

52 week range

6.98 - 28.25

Open12.97
Day High13.04
Day Low12.47
Prev Close13.13
52 Week High28.25
52 Week High Date10/20/25
52 Week Low6.98
52 Week Low Date06/03/25

Latest On Intellia Therapeutics Inc

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trialApril 27, 2026CNBC.com
Stocks making biggest moves midday: Qualcomm, Fermi, Organon and more October 27, 2025CNBC.com
Cramer: I see a brewing risk to market rally — and it's not rising trade tensionsOctober 12, 2025CNBC.com
Stocks making the biggest moves midday: Critical Metals, Comerica, AMD and moreOctober 6, 2025CNBC.com

Key Stats

Market Cap1.819B
Shares Out139.72M
10 Day Average Volume4.58M
Dividend-
Dividend Yield-
Beta1.81

Latest On Intellia Therapeutics Inc

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trialApril 27, 2026CNBC.com
Stocks making biggest moves midday: Qualcomm, Fermi, Organon and more October 27, 2025CNBC.com
Cramer: I see a brewing risk to market rally — and it's not rising trade tensionsOctober 12, 2025CNBC.com
Stocks making the biggest moves midday: Critical Metals, Comerica, AMD and moreOctober 6, 2025CNBC.com

KEY STATS

Open12.97
Day High13.04
Day Low12.47
Prev Close13.13
52 Week High28.25
52 Week High Date10/20/25
52 Week Low6.98
52 Week Low Date06/03/25
Market Cap1.819B
Shares Out139.72M
10 Day Average Volume4.58M
Dividend-
Dividend Yield-
Beta1.81

RATIOS/PROFITABILITY

EPS (TTM)-3.53
P/E (TTM)-3.68
Fwd P/E (NTM)-3.97
EBITDA (TTM)-411.244M
ROE (TTM)-56.34%
Revenue (TTM)66.092M
Gross Margin (TTM)-
Net Margin (TTM)-597.04%
Debt To Equity (MRQ)-

EVENTS

Earnings Date08/05/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)May 14, 2026TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), TriSalus Life Sciences (TLSI) and Fractyl Health, Inc. (GUTS)May 13, 2026TipRanks
Intellia Therapeutics price target raised to $17 from $13 at BernsteinMay 13, 2026TipRanks
Intellia Therapeutics price target lowered to $25 from $30 at H.C. WainwrightMay 13, 2026TipRanks
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)May 13, 2026TipRanks

Profile

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment...

Frank Verwiel M.D.

Independent Chairman of the Board

John Leonard M.D.

President, Chief Executive Officer, Director

Edward Dulac III

Chief Financial Officer, Executive Vice President, Treasurer

Michael Dube

Chief Accounting Officer, Vice President

David Lebwohl M.D.

Executive Vice President, Chief Medical Officer

Address

40 Erie St Ste 130

Cambridge, MA

02139-4254

United States

https://www.intelliatx.com/